QT VASCULAR LTD
(Company Registration No. 201305911K)
(Incorporated in the Republic of Singapore)

RECONSTITUTION OF THE BOARD AND BOARD COMMITTEES

Following completion of the Acquisition and the Subscription announced in a separate announcement released on the SGXNET today, the Board has undertaken a review of the composition of the Board and/or management of the Company for alignment with the strategic direction and operations of the Company.

1. INTRODUCTION

The board of directors (the "**Board**" or "**Directors**") of QT Vascular Ltd (the "**Company**" and together with its subsidiaries, the "**Group**") wishes to announce the following changes to the Board:

2. APPOINTMENT OF NEW EXECUTIVE DIRECTOR

Mr Thomas Tan Gim Chua will be appointed as Chief Executive Office and Executive Director of the Company with effect from 13 January 2022.

Pursuant to Rule 704(6) of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited (the "**Catalist Rules**"), details of Mr Thomas Tan Gim Chua's appointment as Chief Executive Officer and Executive Director of the Company as set out in Appendix 7F of the Catalist Rules are contained in a separate announcement released on 13 January 2022.

3. RESIGNATION OF EXECUTIVE DIRECTOR

The Company's Executive Director, Mr Momi Mimon Brosh, has given notice of his intention to resign as Executive Director of the Company and his resignation will be effective from 13 January 2022. Mr Momi Mimon Brosh will remain as the Chief Executive Officer of TriReme Medical, LLC and continues to manage the existing business of the Company.

Pursuant to Rule 704(6) of the Catalist Rules, details of Mr Momi Mimon Brosh's resignation as Executive Director of the Company as set out in Appendix 7G of the Catalist Rules are contained in a separate announcement released on the SGXNET today.

The Board would like to express its gratitude to Mr Momi Mimon Brosh for his contributions to the Group.

4. RECONSTITUTION OF THE BOARD OF DIRECTORS AND BOARD COMMITTEES

Following the aforesaid changes, the composition of the Board and the Board Committees shall be as follows effective from 13 January 2022:

BOARD OF DIRECTORS	
Name	**Designation**
Ng Boon Eng	Independent Director
Sho Kian Hin	Independent Director
Thomas Tan Gim Chua	Chief Executive Officer and Executive Director

AUDIT COMMITTEE	
Name	**Designation**
Sho Kian Hin	Chairman
Ng Boon Eng	Member

NOMINATING COMMITTEE	
Name	**Designation**
Sho Kian Hin	Chairman
Ng Boon Eng	Member
Thomas Tan Gim Chua	Member

REMUNERATION COMMITTEE	
Name	**Designation**
Ng Boon Eng	Chairman
Sho Kian Hin	Member

The Board notes that the Audit Committee does not meet the requirements of Rule 704(7) of the Catalist Rules and there are also insufficient members in the Remuneration Committee. The Company is currently in the process of assessing suitable candidates to be appointed to the Board to meet the requirements of the respective Board committees and shall endeavour to fill the vacancy before the end of January 2022. The Company will make further announcements on the re-constitution of the Board as and when appropriate.

BY ORDER OF THE BOARD

Sho Kian Hin
Director
14 January 2022

*This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.*

The contact person for the Sponsor is Ms Lim Hui Ling, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.